Overall survival in neuroblastoma by GIBI230 (EUCAIM-SW-079_T-02-04-008)

The tool performs an automatic segmentation of the possible glioblastoma tumours on MRI images and its subregions: necrosis (Intratumoral necrotic core), edema (Peritumoral vasogenic edema), enhancing (Contrast-enhancing tumor region), total (Total tumor including edema and necrosis by a single model) and total-fused (Total tumor fusioning of necrosis+edema+enhancing). It applies preprocessing steps as skull stripping, intra-patient registration, z-score normalization, patching, among others. It takes DICOM images as input and generates tumoral masks in DICOM SEG or NIFTI formats.

The tool performs by deep learning an automatic segmentation of the possible neuroblastoma tumours on Contrast Enhanced CT images (CE-CTs). Model architecture is Unet-based with residual operations, atrous dilation convolution and specific batch generator. It applies preprocessing steps as RAS conversion, resizing, z-score normalization, patching; and postprocessing operations. It takes DICOM images as input and generates tumoral masks in DICOM SEG or NIFTI formats.

A machine learning model that predicts overall survival in patients with glioblastoma, using radiomic and clinical features.

The tool performs an automatic segmentation of the possible DIPG tumours on MR images. DIPG (Diffuse Intrinsic Pontine Glioma), or more recently, DMG (Diffuse Midline Glioma) is a H3 K27M–mutant pediatric brainstem cancer detected in T1W and Flair/T2-weighted magnetic resonance images. The tool includes a complete workflow from DICOM images to DICOM seg tumoral masks.

This tool is specifically designed and validated for automated detection and segmentation of neuroblastic tumours in T2-weighted magnetic resonance images (T2-MR) using deep learning. It processes DICOM or NIfTI input data and outputs in NIFTI or DICOM SEG. TRAINING & VALIDATION COHORTS: Initial Development (Veiga-Canuto 2022): -Training: 106 patients, 5-fold CV (median DSC 0.965 ± 0.018). -Internal validation: 26 patients (median DSC 0.918 ± 0.067). -Sources: La Fe (Spain), SIOPEN HR-NBL1/LINES, St. Anna (Austria), Pisa (Italy). -Mean age: 37.6 ± 39.3 months. -Median tumor volume: 116,518 mm³. External Validation (Veiga-Canuto 2023): -300 patients, 535 independent T2 MRI scans (486 at diagnosis, 49 post-chemotherapy). -Performance: median DSC 0.997 (0.944–1.000), 94% successful detection. -Sources: 12 European countries (HR-NBL1/SIOPEN 119, LINES/SIOPEN 107, German Registry 62, others 12). -Heterogeneous data: 1.5T (435), 3T (100); Siemens (318), Philips (109), GE (105), Canon (3).

High-performance ML research